Adrenocortical carcinoma market hits $22.4m in 2023

In Japan, 200 new cases of ACC were reported in 2023.

The adrenocortical carcinoma (ACC) market across the 7MM region (the United States, EU4 [Germany, France, Italy, and Spain], and Japan) achieved a total valuation of approximately $22.4m in 2023, according to DelveInsight's latest analysis.

ACC refers to a form of cancer that develops in the adrenal cortex, or the outer layer of the adrenal glands, according to Cleveland Clinic. 

The growth of the ACC market was attributed to increasing incidence rates and advancements in diagnostic capabilities.

The incidence of ACC in the 7MM was estimated to be around 1,200 cases in 2023, with projections indicating a continued rise in the coming years. 

The report noted the trend is bolstered by improved diagnostic tools, which enhance detection and understanding of this rare cancer.

In Japan alone, there were approximately 200 new cases of ACC reported in 2023. Experts anticipate a notable compound annual growth rate in incident cases in the region moving forward.

Across the 7MM, ACC showed a gender-specific distribution of approximately 40% in males and 60% in females, underscoring variations in disease prevalence.

Leading companies like Enterome, Bristol-Myers Squibb, Cytovation AS, and Orphagen Pharmaceuticals are actively developing novel treatments for adrenocortical carcinoma. Additionally, Promising therapies in the pipeline include EO2401 + Nivolumab, CyPep-1, and OR-449, among others, expected to enter the market in the near future.

Orphagen Pharmaceuticals announced in January 2023 that the United States Food and Drug Administration (US FDA) granted Rare Pediatric Disease Designation (RPDD) to OR-449, highlighting advancements in pediatric ACC treatment options.